PharmaCorp Rx Inc.
PCRX.V
TSX
| 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | |
|---|---|---|---|---|---|
| Revenue | 259.44% | 1,131.88% | 4,557.93% | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 259.44% | 1,131.88% | 4,557.93% | -- | -- |
| Cost of Revenue | 247.75% | 1,074.37% | 4,178.50% | -- | -- |
| Gross Profit | 278.73% | 1,230.18% | 5,299.58% | -- | -- |
| SG&A Expenses | 143.64% | 142.46% | 333.49% | 524.68% | 492.47% |
| Depreciation & Amortization | 222.56% | 684.86% | 2,700.61% | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 197.35% | 386.38% | 862.50% | 1,419.75% | 1,148.44% |
| Operating Income | 23.30% | 88.40% | 27.43% | -64.59% | -174.08% |
| Income Before Tax | 28.89% | 114.87% | 77.00% | -5.12% | -147.41% |
| Income Tax Expenses | 650.72% | 24,675.00% | 56,800.00% | -- | -- |
| Earnings from Continuing Operations | -31.42% | 108.08% | 63.14% | -4.91% | -125.56% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -263.71% | 5,000.00% | 1,741.67% | -- | -- |
| Net Income | -41.48% | 108.42% | 65.58% | -0.96% | -118.14% |
| EBIT | 23.30% | 88.40% | 27.43% | -64.59% | -174.08% |
| EBITDA | 73.14% | 124.61% | 42.71% | -- | -- |
| EPS Basic | 52.66% | 103.41% | 89.89% | 62.15% | 1.17% |
| Normalized Basic EPS | 70.37% | 106.56% | 94.61% | 63.43% | -0.93% |
| EPS Diluted | 52.66% | 103.41% | 89.89% | 62.15% | 1.17% |
| Normalized Diluted EPS | 70.37% | 106.56% | 94.61% | 63.43% | -0.93% |
| Average Basic Shares Outstanding | 63.25% | 124.22% | 299.47% | 397.62% | 278.38% |
| Average Diluted Shares Outstanding | 63.25% | 124.22% | 299.47% | 397.62% | 278.38% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |